Table 6 Summary of impact of academic detailing visits on primary outcomes
| Â | ITT1 | ITT2 | PPR |
|---|---|---|---|
| Â | Step change [95% Wald CI] | ||
Odds of being reimbursed for an analgesic or NSAID, in intervention compared to control group (PO1) | 0.9973 [0.9860; 1.0088] | 0.9929 [0.9780; 1.0081] | 1.0218 [0.9982; 1.0459] |
Average defined daily dose of paracetamol per patient reimbursed for paracetamol per month, in intervention compared to control group (PO2) | − 0.3106 [− 0.8493; 0.2281] | − 0.2442 [− 0.8677; 0.3793] | − 0.2665 [− 0.8491; 0.3161] |
Odds of being reimbursed for a recommended NSAID when reimbursed for any NSAID, in intervention compared to control group (PO3) | 1.1887* [1.1004; 1.2841] | 1.2158* [1.1276; 1.3109] | 1.2158* [1.1276; 1.3109] |
Odds of being reimbursed for an NSAID and a PPI when reimbursed for an NSAID, in intervention compared to control group (PO4) | 1.0194 [0.9419; 1.1032] | 1.0188 [0.9336; 1.1117] | 1.0050 [0.9534; 1.0593] |
| Â | Change in trend [95% Wald CI] | ||
Odds of being reimbursed for an analgesic or NSAID, in intervention compared to control group (PO1) | 0.9882* [0.9790; 0.9975] | 0.9896* [0.9806; 0.9987] | 0.9990 [0.9945; 1.0035] |
Average defined daily dose of paracetamol per patient reimbursed for paracetamol per month, in intervention compared to control group (PO2) | 0.0389 [− 0.1446; 0.2224] | 0.0937 [− 0.0686; 0.2560] | 0.1400 [− 0.0513; 0.3313] |
Odds of being reimbursed for a recommended NSAID when reimbursed for any NSAID, in intervention compared to control group (PO3) | 0.9902 [0.9775; 1.0030] | 0.9894 [0.9776; 1.0013] | 0.9882 [0.9753; 1.0012] |
Odds of being reimbursed for an NSAID and a PPI when reimbursed for an NSAID, in intervention compared to control group (PO4) | 0.9940 [0.9765; 1.0118] | 0.9944 [0.9762; 1.0129] | 0.9968 [0.9770; 1.0170] |